Next 10 |
home / stock / vigl / vigl articles
Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the not...
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negoti...
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to h...
WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to...
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to...
WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to...
WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to...
Poster highlights clinical overlap of ALSP and multiple sclerosis (MS) and details patients' barriers to genetic testing WATERTOWN, Mass., F...
WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to...
News, Short Squeeze, Breakout and More Instantly...
Vigil Neuroscience Inc. Company Name:
VIGL Stock Symbol:
NASDAQ Market:
Vigil Neuroscience Inc. Website:
2024-06-28 09:15:05 ET Wedbush analyst issues OUTPERFORM recommendation for VIGL on June 28, 2024 07:53AM ET. The previous analyst recommendation was Outperform. VIGL was trading at $4.48 at issue of the analyst recommendation. Historical Analyst Recommendations La...
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company’s small molecule TREM2 agonist program, including VG-3927, currently in phase 1 clinical studies - ...